drugset / Trial / NCT05036473
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.
Timeline
- Start
- 2021-11-11
- Primary completion
- 2022-12-28
- Completion
- 2022-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbidopa | Unknown | 25 mg | Oral |
| Subject | Carbidopa | Unknown | 50 mg | Oral |
| Subject | Levodopa | Small molecule | 100 mg | Oral |
| Subject | Levodopa | Small molecule | 150 mg | Oral |
| Subject | Levodopa | Small molecule | 200 mg | Oral |